- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06192316
Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Examine the effects of nicotine concentration and source claims on engagement with ONP packaging using laboratory-based psychophysiological assessment.
II. Examine the effects of nicotine concentration and source claims on participant self-reported ONP perceptions, behavioral intentions, and ONP trial.
This is an experimental behavioral study. Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: The Ohio State University Comprehensive Cancer Center
- Phone Number: 800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Darren Mays, MPH, PhD
- Phone Number: 614-366-2953
-
Principal Investigator:
- Darren Mays, MPH, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Young adult susceptible non-users aged 18-24 who have never used ONPs and have never used but are susceptible to using either:
- combustible tobacco only (cigarettes, cigars, waterpipe)
- non-combustible tobacco only (ST, ECs, heated tobacco products)
- or both combustible and non-combustible tobacco (i.e., dual susceptibility)
Adult tobacco users aged 18-65 who have never used ONPs OR have used ONPs >3 months ago and 10 times or less in their lifetime. All adult tobacco users must also be:
- exclusive combustible tobacco users
- exclusive non-combustible tobacco users
dual users
- For adult tobacco users, we will define current use as use of combustible and/or non-combustible tobacco every day or some days for 6 months or longer
- Willing and able to complete an in-person lab visit.
Exclusion Criteria:
- Age < 18 or > 65
- Are not susceptible non-users or current tobacco users
- Are unwilling or unable to complete and in person lab visit.
- Have used ONPs within the past 3 months
- Have used ONPs more than 10 times in their lifetime
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nicotine Concentration: None Displayed; Nicotine Source Claim 1
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: None Displayed; Nicotine Source Claim 2
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: None Displayed; Nicotine Source Claim 3
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: Low; Nicotine Source Claim 1
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: Low; Nicotine Source Claim 2
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: Low; Nicotine Source Claim 3
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: High; Nicotine Source Claim 1
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: High; Nicotine Source Claim 2
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
|
Experimental: Nicotine Concentration: High; Nicotine Source Claim 3
Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study.
Participants also complete questionnaires on study.
|
Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, "Tobacco Free," "Synthetic Nicotine") between-subjects design.
We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions.
Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to.
Within each condition, pack images will vary by 4 brands and 4 flavors per brand.
While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Attention - Dwell Time
Time Frame: 1 day (Single Time Point: During Exposure)
|
Visual attention will be measured via eye movements using SmartEye AI-X eye tracker with a 60 Hz sampling rate.
Areas of interest (AOIs) will be predefined for each pack image including: 1) Full pack image; 2) Nicotine concentration; 3) Nicotine source claim; 4) Branding (i.e., brand name, flavors); 5) Warning label.
A primary outcome for visual attention will be dwell time on AOIs.
|
1 day (Single Time Point: During Exposure)
|
|
Visual Attention - Time to First Fixation
Time Frame: 1 day (Single Time Point: During Exposure)
|
Visual attention will be measured via eye movements using SmartEye AI-X eye tracker with a 60 Hz sampling rate.
Areas of interest (AOIs) will be predefined for each pack image including: 1) Full pack image; 2) Nicotine concentration; 3) Nicotine source claim; 4) Branding (i.e., brand name, flavors); 5) Warning label.
A primary outcome for visual attention will be time to first fixation on AOIs.
|
1 day (Single Time Point: During Exposure)
|
|
Visual Attention - Number of Fixations
Time Frame: 1 day (Single Time Point: During Exposure)
|
Visual attention will be measured via eye movements using SmartEye AI-X eye tracker with a 60 Hz sampling rate.
Areas of interest (AOIs) will be predefined for each pack image including: 1) Full pack image; 2) Nicotine concentration; 3) Nicotine source claim; 4) Branding (i.e., brand name, flavors); 5) Warning label.
A primary outcome for visual attention will be number of fixations (i.e., saccades) to AOIs.
|
1 day (Single Time Point: During Exposure)
|
|
Cognitive Attention
Time Frame: 1 day (Single Time Point: During Exposure)
|
Conceptualized as the cognitive resources allocated to encode a message into working memory, attention will be operationalized as the difference in heart rate (HR) between a baseline period prior to each pack image and during each second of the pack image exposure assessed with ECG.
Beats per minute (BPM) will be collected with the Shimmer3 sampled at 512 Hz.
This is an established psychophysiological measure of cognitive resources devoted to stimuli processing.
|
1 day (Single Time Point: During Exposure)
|
|
Arousal
Time Frame: 1 day (Single Time Point: During Exposure)
|
Arousal is an indicator of physiological activation of the sympathetic nervous system and will be measured by skin conductance using Shimmer3 Galvanic Skin Response EDA sensors sampled at 128 Hz
|
1 day (Single Time Point: During Exposure)
|
|
Recall
Time Frame: 1 day (Single Time Point: During Exposure)
|
We will capture unaided recall, a measure of storage in memory, via 3 open ended questions on a questionnaire pertaining to nicotine concentration, brand names, and source information corresponding to conditions to which participants are randomized.
Responses will be coded, and coding reliability will be established, to create a score with higher values reflecting better recall of information about nicotine dimensions in the stimuli.
|
1 day (Single Time Point: During Exposure)
|
|
ONP Perceptions
Time Frame: 1 day (Single Time Point: During Exposure)
|
We will capture perceptions of ONPs with 7 items that align with expert recommendations for assessing cognitive and affective aspects of tobacco risk perceptions.
Items will assess perceived risk of health harm from ONPs, perceived risk of addiction from ONPs, worry about harm, and worry about addiction.
The items are on a 1-7 response scale, have excellent reliability, and are averaged to create an overall score.
|
1 day (Single Time Point: During Exposure)
|
|
ONP Perceptions Relative to Other Products
Time Frame: 1 day (Single Time Point: During Exposure)
|
We will also capture perceived harm and addictiveness of ONPs relative to cigarettes, smokeless tobacco, and electronic cigarettes using valid items on a 1-5 response scale.
|
1 day (Single Time Point: During Exposure)
|
|
ONP Intentions
Time Frame: 1 day (Single Time Point: During Exposure)
|
We will assess curiosity, interest, and likelihood of using ONPs post-exposure.
These are valid predictors of future use of novel tobacco and nicotine products among never users.
Items are on a 1-7 scale, have excellent reliability, and are combined to create an overall ONP intentions score.
|
1 day (Single Time Point: During Exposure)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ONP Trial (Lapse Task)
Time Frame: Single Time Point for 25 Minutes
|
This is a valid behavioral measure that was originally developed for smoking cue reactivity research and used in prior work by others and our team.
The lapse task will assess ONP trial, time to trial, and ONP product selection.
|
Single Time Point for 25 Minutes
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Darren Mays, MPH, PhD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-23115
- NCI-2023-08947 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U54CA287392 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behavior, Risk
-
Ohio State University Comprehensive Cancer CenterBreast Cancer Research FoundationRecruiting
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompletedRisk ReductionSouth Africa
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompleted
-
Bournemouth UniversityDorset HealthCare University NHS Foundation TrustWithdrawnRisk Behavior | Violence | Risk Behavior, Health
-
University of California, San FranciscoUniversity of MiamiCompletedRisk ReductionUnited States
-
Hadassah Medical OrganizationHebrew University of JerusalemNot yet recruitingHealth Behavior | Food Habits | Lifestyle Risk Reduction
-
Hadassah Medical OrganizationCompletedHealth Behavior | Food Habits | Lifestyle Risk ReductionIsrael
-
Vivoptim SolutionsCompletedCardiovascular Risk | Lifestyle Risk Reduction | Cardiovascular Disease Prevention | Lifestyle (Sedentary Behavior and Physical Activity) | Health Behavior ChangeFrance
-
Istituto per la Ricerca e l'Innovazione BiomedicaFondazione Don Carlo Gnocchi Onlus; Universita degli Studi di Palermo; Medilink...RecruitingHealth Promotion | Life Style, Healthy | Risk ReductionItaly
-
National Taiwan University HospitalCompletedLifestyle Risk Reduction | Elderly Adults | Community DwellingTaiwan
Clinical Trials on 3x3 between-subjects experimental exposure
-
University of Texas at AustinCompleted
-
Lehigh UniversityCompletedHealthyUnited States
-
Lehigh UniversityEnrolling by invitationHealthyUnited States
-
University of NottinghamCompleted
-
Universidad de GranadaCompletedFibromyalgia SyndromeSpain
-
Riphah International UniversityCompletedComparison of Kinesiotaping and Graded Exposure Therapy on Kinesiophobia in Post-Mastectomy PatientsPost-mastectomy Pain SyndromePakistan
-
University Hospital, BrestRecruitingColorectal CancerFrance
-
ALI BAHADIRLIBursa Yüksek İhtisas Education and Research HospitalCompletedGestational Diabetes Mellitus in PregnancyTurkey
-
Nanyang Technological UniversityCompleted
-
Universidad de GranadaCompletedFibromyalgia SyndromeSpain